Novartis drug helps rare tumors, filing this year (Reuters, 11 October 2010)

11 Oct 2010


Novartis have presented data from a phase III study of their pancreatic neuroendocrine tumour drug Afinitor (generic name everolimus) at the European Society for Medical Oncology congress in Milan.

Full article


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story